Prospective feasibility of a minimal BH3 profiling assay in acute myeloid leukemia
Cytometry Part B: Clinical Cytometry · 2025
DOI: 10.1002/cyto.b.22217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2025. Verfasst von Kim Pacchiardi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, Génomes, biologie cellulaire et thérapeutique U944, INSERM, CNRS, Paris, France. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Proto-Oncogene Proteins c-bcl-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Association Laurette Fugain, Agence Nationale de la Recherche, Fondation ARC pour la Recherche sur le Cancer.
Abstract (Originalsprache)
BH3 profiling can assess global mitochondrial priming and dependence of leukemic cells on specific BH3 anti‐apoptotic proteins such as BCL‐2. In acute myeloid leukemia (AML), proof‐of‐concept prognostic studies have been performed on archived samples variably accounting for molecular genetics. We undertook a single‐center feasibility study of a simplified flow‐based assay to determine the absolute mitochondrial priming and BCL‐2 dependence in consecutive AML patients. When possible, results on the leukemic fraction were normalized to the cognate lymphocyte population (relative priming and BCL‐2 dependence). Samples from 97 (89.8%) of the 108 referred patients were successfully processed. Relative priming and BCL‐2 dependence could be determined in 62 (67.4%) and 67 (62.0%) samples, respectively. Absolute mitochondrial priming was lower in patients having previously failed intensive chemotherapy compared to chemotherapy‐naïve patients ( p = 0.01), but its prognostic impact was limited. Conversely, relative BCL‐2 independence tended to predict worse EFS (HR = 2.51, p = 0.07) and OS (HR = 2.79, p = 0.10) independently of adverse genetic risk. Our results show that simplified BH3 profiling can be prospectively assessed in AML patients but that its prognostic use may require internal normalization. Future studies should compare its relevance with other functional assays such as ex vivo drug testing or BH3 protein expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, Génomes, biologie cellulaire et thérapeutique U944, INSERM, CNRS, Paris, France.
- Laboratoire d'Hématologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
- Département Hématologie et Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
ORCID-Profile: Raphael Itzykson
Förderung
- Association Laurette Fugain
- Agence Nationale de la Recherche
- Fondation ARC pour la Recherche sur le Cancer
- Institut National Du Cancer
Zitieren
APA
Pacchiardi, K., de Marcellus, V., Huynh, T., Fodil, S., Kim, R., Bello, R. D., Fontaine, M., Lonchamp, C., Chat, L., Aguinaga, L., Lengliné, E., Sébert, M., Raffoux, E., Adès, L., Dombret, H., Clappier, E., Puissant, A., Mathis, S., Chauvel, C., & Itzykson, R. (2025). Prospective feasibility of a minimal BH3 profiling assay in acute myeloid leukemia. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.22217
Vancouver
Pacchiardi K, de Marcellus V, Huynh T, Fodil S, Kim R, Bello RD, et al. Prospective feasibility of a minimal BH3 profiling assay in acute myeloid leukemia. Cytometry Part B: Clinical Cytometry. 2025. doi:10.1002/cyto.b.22217
BibTeX
@article{Pacchiardi2025,
author = {Pacchiardi, Kim and de Marcellus, Victoire and Huynh, Tony and Fodil, Sofiane and Kim, Rathana and Bello, Reinaldo Dal and Fontaine, Morgane and Lonchamp, Catherine and Chat, Laureen and Aguinaga, Lorea and Lengliné, Etienne and Sébert, Marie and Raffoux, Emmanuel and Adès, Lionel and Dombret, Hervé and Clappier, Emmanuelle and Puissant, Alexandre and Mathis, Stéphanie and Chauvel, Clémentine and Itzykson, Raphael},
title = {Prospective feasibility of a minimal BH3 profiling assay in acute myeloid leukemia},
journal = {Cytometry Part B: Clinical Cytometry},
year = {2025},
doi = {10.1002/cyto.b.22217}
}
EUVIMED